Control study of melphalan instead of cyclophosphamide as a myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of myeloid malignancies / 中华血液学杂志
Chinese Journal of Hematology
; (12): 835-839, 2015.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-296140
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate melphalan instead of cyclophosphamide in modified busulfancyclophosphamide regimen as a new myeloablative conditioning regimen for the treatment of myeloid malignancies patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).</p><p><b>METHODS</b>The clinic data of 94 myeloid malignancies patients undergoing allogeneic HSCT were analyzed, of which 48 patients received Bu+Cy+Flu+Ara-C, 46 cases Bu+Mel+Flu+Ara-C regimens. Rregimen-related toxicity, engraftment, graft- versus-host disease(GVHD), infection condition, non- relapse mortality, and overall survival were compared between the two groups.</p><p><b>RESULTS</b>All patients achieved neutrophil engraftment. The incidence of grade Ⅲ-Ⅳ oral mucositis and diarrhea in BMFA group was higher than in BCFA group(P<0.05). The incidence of acute GVHD in BMFA group was also higher than in BCFA group but without statistically significant difference(36.5% over 56.5%, P=0.100). With a median follow up of 42 months, the incidence of no relapse mortality in BCFA group was 12.5% and 19.6% in BMFA group(P=0.400). The relapse rate in BMFA group(4.3%)was significantly lower than in BCFA group (25.0%, P=0.009). The overall survival rates were(71.8±6.7)% and(76.1±6.3)%(P=0.852), and diseasefree survival rates were(67.8±8.9)% and(76.1±6.3)%(P=0.567)were comparable between BCFA group and BMFA group.</p><p><b>CONCLUSION</b>Melphalan instead of cyclophosphamide as a new myeloablative conditioning regimen had lower relapse and satisfied disease-free survival rates, but the risk of regimenrelated toxicity and GVHD should be taken into consideration.</p>
Texto completo:
Disponível
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
/
ODS3 - Saúde e Bem-Estar
/
Doenças Negligenciadas
/
ODS3 - Meta 3.3 Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
Problema de saúde:
Objetivo 9: Redução de doenças não transmissíveis
/
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
/
Diarreia
/
Infecções Diarreicas
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Terapêutica
/
Transplante Homólogo
/
Indução de Remissão
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Taxa de Sobrevida
/
Transplante de Células-Tronco Hematopoéticas
/
Intervalo Livre de Doença
/
Neoplasias Hematológicas
/
Condicionamento Pré-Transplante
/
Ciclofosfamida
Limite:
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Hematology
Ano de publicação:
2015
Tipo de documento:
Artigo